CD-56 Immunohistochemistry at Test Zone Diagnostic Center

CD-56 Immunohistochemistry at Test Zone Diagnostic Center

CD-56 Immunohistochemistry at Test Zone Diagnostic Center is a highly specialized pathology investigation used to detect the expression of Cluster of Differentiation 56 (CD56), also known as Neural Cell Adhesion Molecule (NCAM). This glycoprotein is critically involved in cell-to-cell adhesion, neurite outgrowth, synaptic plasticity, and intracellular signaling. In clinical medicine, CD56 serves as an invaluable diagnostic biomarker. It is primarily expressed on natural killer (NK) cells, a subset of T lymphocytes, neuroectodermal tissues, and cells of neuroendocrine origin. By utilizing advanced immunohistochemical (IHC) staining techniques, pathologists at Test Zone Diagnostic Center can precisely identify the presence, distribution, and intensity of CD56 expression within tissue specimens. This diagnostic capability is essential for characterizing various malignancies, evaluating reproductive health, and guiding targeted therapeutic strategies.

The diagnostic value of CD-56 Immunohistochemistry lies in its high sensitivity for neuroendocrine differentiation and specific hematologic lineages. When a patient undergoes a biopsy or surgical resection, the tissue is processed, embedded in paraffin, and sectioned into ultra-thin slices. The IHC process involves applying highly specific monoclonal antibodies directed against the CD56 antigen. If the antigen is present in the tissue, the antibodies bind to it, and a specialized detection system visualizes this binding under a light microscope as a distinct brown or red stain. This allows our consultant pathologists to make highly accurate diagnoses, distinguishing between benign and malignant conditions, and identifying the exact cellular origin of poorly differentiated tumors.

Clinical Procedure: What to Expect

Patient Preparation

Because CD-56 Immunohistochemistry is performed on tissue samples obtained via biopsy or surgical resection, patient preparation depends entirely on the primary procedure used to collect the specimen. Test Zone Diagnostic Center recommends the following general guidelines:

• Biopsy Preparation: If you are undergoing an active biopsy (such as an endometrial biopsy, lung biopsy, or lymph node biopsy), follow all pre-operative instructions provided by your clinical specialist. This may include fasting for 6 to 8 hours if sedation is required.
• Medication Review: Inform your physician about all medications you are currently taking, particularly anticoagulants (blood thinners) like aspirin, warfarin, or clopidogrel, which may need to be temporarily discontinued before a biopsy.
• Submission of Pre-existing Blocks: If you are submitting a pre-existing formalin-fixed paraffin-embedded (FFPE) tissue block or unstained slides from another facility, no physical preparation is required. Ensure that the specimen is accompanied by the original histopathology report and transport it at room temperature, avoiding extreme heat or cold.
• Menstrual Cycle Timing: For endometrial biopsies evaluating uterine natural killer (uNK) cells, the procedure is typically scheduled during the mid-luteal phase (usually days 21 to 23 of a standard 28-day cycle). Confirm the timing with your gynecologist.

During the Procedure

The laboratory phase of CD-56 Immunohistochemistry is conducted entirely within the histopathology department of Test Zone Diagnostic Center. The process involves several highly controlled steps to ensure diagnostic accuracy:

• Specimen Reception and Accessioning: The tissue specimen is received, verified against clinical details, and assigned a unique laboratory identification number to prevent any risk of sample mix-up.
• Tissue Processing and Embedding: The tissue is fixed in 10% neutral buffered formalin, dehydrated through graded alcohols, cleared in xylene, and embedded in paraffin wax to form a solid block.
• Microtomy: A skilled histotechnologist cuts ultra-thin sections (approximately 3 to 4 micrometers thick) using a precision microtome and mounts them onto specialized charged glass slides.
• Antigen Retrieval: The slides undergo deparaffinization and rehydration. Heat-Induced Epitope Retrieval (HIER) is performed using a buffer solution to break formalin-induced cross-links, exposing the CD56 epitopes for antibody binding.
• Antibody Incubation: The tissue sections are incubated with a highly specific primary anti-CD56 monoclonal antibody under optimized temperature and time conditions.
• Detection and Visualization: A secondary antibody conjugated with an enzyme (such as horseradish peroxidase) is applied, followed by a chromogen substrate (usually diaminobenzidine, or DAB). This produces a visible, localized brown precipitate at the site of CD56 expression.
• Counterstaining and Mounting: The slides are counterstained with hematoxylin to visualize cellular nuclei, dehydrated, cleared, and coverslipped for permanent preservation.
• Pathologist Evaluation: A consultant pathologist examines the stained slides under a high-resolution light microscope, assessing the staining pattern (membranous or cytoplasmic), intensity, and percentage of positive cells.

When is a CD-56 Immunohistochemistry Performed?

Evaluation of Neuroendocrine Tumors

Physicians request CD-56 Immunohistochemistry when they suspect a neuroendocrine tumor (NET). CD56 is highly expressed in neuroendocrine cells throughout the body. In patients presenting with pulmonary nodules, chronic cough, or hemoptysis, this marker helps identify small cell lung carcinoma (SCLC) and large cell neuroendocrine carcinoma. It is also used to characterize carcinoid tumors of the gastrointestinal tract, pheochromocytomas of the adrenal gland, and medullary thyroid carcinomas. Identifying CD56 expression helps confirm the neuroendocrine lineage of these aggressive or indolent neoplasms, allowing oncologists to formulate precise, targeted treatment plans.

Diagnosis of Hematologic Malignancies

In hematopathology, CD-56 IHC is a vital tool for diagnosing and classifying specific lymphomas and leukemias. It is particularly useful when evaluating suspected extranodal NK/T-cell lymphoma, nasal type, which is an aggressive malignancy characterized by CD56-positive cytotoxic T cells or natural killer cells. Additionally, CD56 expression is evaluated in suspected cases of multiple myeloma. While normal plasma cells are typically CD56-negative, neoplastic plasma cells in multiple myeloma frequently express CD56. This differentiation is crucial for distinguishing neoplastic plasma cell proliferations from reactive plasmacytosis and for monitoring minimal residual disease.

Assessment of Endometrial Receptivity and Recurrent Pregnancy Loss

Gynecologists and reproductive endocrinologists frequently order CD-56 Immunohistochemistry on endometrial biopsy specimens. Uterine natural killer (uNK) cells play a pivotal role in endometrial decidualization, angiogenesis, and trophoblast invasion during early pregnancy. An abnormal density or distribution of CD56-positive uNK cells in the endometrium during the implantation window has been linked to recurrent pregnancy loss (RPL) and repeated implantation failure (RIF) during in vitro fertilization (IVF) cycles. Quantifying these cells helps specialists understand the uterine microenvironment and make informed decisions regarding immunomodulatory therapies.

Characterization of Central Nervous System and Neural Tumors

Because CD56 is a neural cell adhesion molecule, it is widely expressed in tissues derived from the neuroectoderm. Neuropathologists utilize CD-56 Immunohistochemistry to evaluate tumors of the central and peripheral nervous systems. It assists in the diagnosis of neuroblastomas, ganglioneuromas, astrocytomas, ependymomas, and schwannomas. When patients present with neurological deficits, headaches, or space-occupying lesions on MRI, a biopsy evaluated with CD56 helps confirm the neural or glial origin of the tumor, distinguishing it from metastatic non-neural epithelial malignancies.

Differentiation of Undifferentiated Neoplasms

When a patient presents with metastatic disease of unknown primary origin, the tumor cells may appear highly anaplastic or poorly differentiated under standard hematoxylin and eosin (H&E) staining. In such cases, pathologists employ a panel of immunohistochemical markers, including CD56, to determine the tumor’s lineage. Positive CD56 staining, in conjunction with other markers like synaptophysin, chromogranin A, and cytokeratins, helps narrow down the differential diagnosis to a neuroendocrine or neuroectodermal origin, which is critical for selecting the appropriate systemic chemotherapy or radiotherapy regimen.

What Does a CD-56 Immunohistochemistry Detect?

CD-56 Immunohistochemistry at Test Zone Diagnostic Center is designed to detect and characterize specific cellular profiles. The test identifies:

• Strong membranous expression of CD56 in small cell lung carcinoma cells.
• Diffuse CD56 positivity in classic carcinoid tumors of the lung and gastrointestinal tract.
• Expression of CD56 in neoplastic plasma cells, aiding in the diagnosis of multiple myeloma.
• The presence and density of CD56-positive uterine natural killer (uNK) cells in endometrial tissue.
• CD56 positivity in extranodal NK/T-cell lymphoma, nasal type, confirming its cytotoxic lineage.
• Expression in neuroblastoma cells, distinguishing them from other pediatric small round blue cell tumors.
• Membranous staining in schwannomas and neurofibromas of the peripheral nervous system.
• CD56 expression in medullary thyroid carcinoma, differentiating it from follicular or papillary thyroid cancers.
• Positivity in pheochromocytomas and paragangliomas.
• Expression in normal and neoplastic astrocytes, oligodendrocytes, and ependymal cells.
• CD56 positivity in Wilms’ tumor (nephroblastoma) and other embryonal tumors.
• Presence of CD56 in synovial sarcoma, helping differentiate it from other spindle cell neoplasms.
• Expression in Merkel cell carcinoma, a highly aggressive neuroendocrine tumor of the skin.
• Absence of CD56 in normal, reactive plasma cells, helping rule out plasma cell dyscrasias.
• CD56 expression in pancreatic neuroendocrine tumors (PanNETs).
• Positivity in retinoblastoma and other neuroectodermal ocular tumors.
• Staining in olfactory neuroblastoma (esthesioneuroblastoma) of the nasal cavity.
• CD56 expression in pituitary adenomas.
• Presence of CD56 in certain ovarian and testicular germ cell tumors with neuroectodermal differentiation.
• Staining patterns in skeletal muscle fibers, which may show CD56 expression during regeneration or denervation.
• CD56 expression in cholangiocarcinoma and certain hepatocellular carcinomas with neuroendocrine features.
• The exact percentage and localization of CD56-positive cells within a given tissue microenvironment.

Turnaround Time and Report Access at Test Zone Diagnostic Center

At Test Zone Diagnostic Center, we understand that timely and accurate pathology reports are critical for clinical decision-making and patient peace of mind. Immunohistochemistry is a multi-step, highly technical process that requires careful tissue preparation, precise staining, and detailed microscopic evaluation by our consultant pathologists. Consequently, the turnaround time for CD-56 Immunohistochemistry is typically 3 to 5 working days from the receipt of the specimen or paraffin block at our central laboratory.

Once the pathologist completes the evaluation and signs off on the report, patients and referring physicians are notified immediately via SMS. Reports can be accessed and downloaded securely through the Test Zone Diagnostic Center online portal or mobile application. Physical copies of the report, along with the stained slides and paraffin blocks, can also be collected from our main center. This seamless digital access ensures that oncologists, gynecologists, and other specialists can promptly review the findings and initiate the appropriate treatment plan without delay.

CD-56 Immunohistochemistry Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Endometrium (uNK Cells)	Physiological levels of CD56+ uNK cells (typically 10-15% of stromal cells in the mid-luteal phase).	Significantly elevated or depleted CD56+ uNK cell count, associated with recurrent pregnancy loss or implantation failure.
Lung Biopsy (Neuroendocrine)	Negative CD56 expression in normal bronchial epithelial cells.	Diffuse, strong membranous CD56 positivity, indicating small cell lung carcinoma or carcinoid tumor.
Lymph Node (NK/T-cell)	Occasional scattered CD56+ NK cells in normal lymphoid tissue.	Dense sheets of atypical, large CD56+ lymphocytes, diagnostic of extranodal NK/T-cell lymphoma.
Bone Marrow (Plasma Cells)	Normal plasma cells are CD56-negative.	CD56-positive neoplastic plasma cells, indicating multiple myeloma or monoclonal gammopathy of undetermined significance (MGUS).
Peripheral Nerve Tissue	Normal myelin sheath and Schwann cells show moderate CD56 expression.	Intense, diffuse CD56 expression in schwannomas or neurofibromas; altered expression in demyelinating neuropathies.
Thyroid Gland	Normal follicular cells are CD56-negative.	Strong CD56 positivity in medullary thyroid carcinoma; loss of CD56 expression in papillary thyroid carcinoma.
Adrenal Gland	Normal adrenal medullary cells show moderate CD56 expression.	Strong, diffuse CD56 expression in pheochromocytoma.
Skeletal Muscle	Mature, healthy skeletal muscle fibers are CD56-negative.	CD56 expression in regenerating muscle fibers, denervated muscle, or rhabdomyosarcoma.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Test Zone Diagnostic Center for CD-56 Immunohistochemistry?

• Experienced Healthcare Professionals: Our pathology department is led by highly qualified consultant pathologists with specialized training in histopathology and immunohistochemistry.
• Patient-Focused Care: We prioritize patient comfort, clear communication, and compassionate service throughout the diagnostic journey.
• Quality Diagnostic Services: Test Zone Diagnostic Center adheres to strict international quality control standards, ensuring highly accurate and reproducible IHC staining.
• Professional Reporting: Our reports are comprehensive, detailed, and structured to provide clear, actionable insights for referring clinicians.
• Modern Diagnostic Approach: We utilize advanced, automated immunohistochemical staining platforms that minimize human error and optimize staining quality.
• Comfortable Environment: Our diagnostic centers are designed to provide a clean, safe, and welcoming environment for patients during sample submission.
• Convenient Location: Strategically located in Lahore, our center is easily accessible to patients from all parts of the city and surrounding regions.
• Commitment to Accurate Diagnosis: We understand the critical impact of pathology results on cancer treatment and reproductive medicine, driving our commitment to absolute diagnostic precision.